Answers are grounded in this paper and cite their sources.
Cannabigerol (CBG) is a non-intoxicating phytocannabinoid under investigation as a neuropsychiatric drug candidate. Although historically studied primarily for its role in cannabinoid biosynthesis, CBG has a multitarget pharmacological profile distinct from those of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC). Experimental studies implicate cannabinoid receptors, α2A-adrenoceptors, 5-HT1A receptors, transient receptor potential channels, peroxisome proliferator-activated receptor-γ, and voltage-gated sodium channels, alongside effects on neuroinflammation, oxidative stress, neuronal survival, and excitability. These findings support investigation across several neuropsychiatric conditions, but their clinical relevance remains uncertain. Human studies have begun to characterize oral pharmacokinetics, the influence of food and formulation on systemic exposure, and acute tolerability. A single-dose controlled study of healthy adults reported preliminary effects on anxiety and stress, whereas a repeated-dose randomized trial in participants with problematic sleep found no superiority over placebo on its primary outcome. Brain exposure, target engagement, exposure–response relationships, drug interactions, therapeutic dosing, and long-term safety remain insufficiently defined. This review critically evaluates the pharmacological, preclinical, and human evidence for CBG and identifies the barriers to clinical translation. Despite a plausible experimental rationale, efficacy has not been established for any neuropsychiatric disorder.
No takes yet. Share an insight, caveat, or question.
Crippa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: